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Highlights   
 Purification strategy for native Sigma GST protein  from liver fluke 
 Separation of Mu and Sigma GST class proteins  by isoelectric point difference  
 Proteomics validation of column chromatography purification  
 
Abstract 
Fascioliasis is a parasitic disease of grazing livestock and a threat to global food security by 
significantly reducing the production value of sheep, goats and cattle. Moreover, the zoonotic 
parasite is also a re-emerging food borne threat to human populations. Driven by climate 
change, the prevalence of fascioliasis is set to increase. Efforts to control the main causative 
agent, Fasciola hepatica, are hampered by short lived chemotherapy approaches that are 
becoming increasingly obsolete due to therapeutic failure and resistance. A protective 
vaccine is urgently needed. A recombinant form of Sigma class glutathione transferase 
(Hematopoietic Prostaglandin D synthase) from F. hepatica (FhGSTS1) with confirmed 
prostaglandin synthase activity shows immune-modulation activity via suppression of Th17 
responses in host dendritic cells. In vaccine trials recombinant FhGSTS1 reduces liver 
pathology but not worm burden. Native FhGSTS1 is yet to be tested for immune-modulation 
activities or for vaccine potential, primarily due to the technical difficulty in purifying FhGST-
S1 away from the other more abundant GST members in F. hepatica cytosol.  This paper 
reports a pipeline for the purification of native FhGSTS1 using a two-step process consisting 
of glutathione-agarose affinity and cationic exchange chromatography. The methodology 
allows for the isolation of purified and active FhGSTS1 or Sigma GSTs from other sources 
for analytical biochemical and immunological studies.  
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Abbreviations: 1-Chloro-2,4-dinitrobenzene (CDNB), Fasciola hepatica Sigma class 
glutathione transferase (FhGSTS1), reduced glutathione (GSH). 
 
Keywords: Glutathione transferase; Fasciola hepatica; vaccine; chromatography 
 
1.  Introduction 
Fasciola hepatica, is a major parasite of livestock and humans in temperate regions 
throughout the world. Fascioliasis negatively impacts upon the welfare and production of 
domestic livestock, with infected animals exhibiting marked decreases in the yields of meat, 
milk and wool, reduced fertility and risk of sudden early death [1]. This loss of production is a 
threat to global food security, with an estimated annual cost of at least $3 billion [2]. In 
addition, F. hepatica is re-emerging as a global food borne disease of human populations, 
with up to 17 million people infected and a further 180 million at risk [3]. 
Control of F. hepatica has been mainly achieved through the application of short-lived 
anthelmintic chemicals to treat both infected livestock and humans. The drug of choice for 
especially the acute disease is Triclabendazole (TCBZ); unique in its ability to target both 
pathogenic juvenile and adult F. hepatica [4]. However, the over reliance on TCBZ has 
driven the emergence and spread of drug resistant liver fluke isolates, further threatening 
problematic disease control [5]. Moreover, the mechanisms underpinning TCBZ resistance 
are currently unknown, hindering the detection of resistance at an early stage.  
The declining global efficacy of TCBZ is unfortunately coupled with climate change 
increasing disease incidence and range [6]. In the continued absence of a TCBZ 
replacement there is renewed drive to develop a commercially sustainable liver fluke 
vaccine.  Many vaccine targets for F. hepatica have been identified and experimentally 
tested, most show too low protection rates for commercial development and some fail when 
vaccine trials are repeated [7].  A panel of the most promising liver fluke vaccine candidates 
include members of the soluble glutathione transferase superfamily, such as recently 
discovered Sigma class glutathione transferase (FhGSTS1), a Hematopoietic Prostaglandin 
D synthase [8,9,10,11]. 
FhGSTS1 has been shown to be secreted from liver fluke via extracellular vesicles, exhibit 
prostaglandin synthase activity, suppress a Th17 response in host dendritic cells via TLR-4 
dependent binding and stimulate increased prostaglandin release from host cells [12, 13, 
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14]. These abilities suggest that FhGSTS1 has keys establishment roles within the host and 
importantly the location of this protein, in the tegument, fluke secretions [15] and 
extracellular vesicles [12], makes it susceptible as part of a blocking antibody vaccine 
strategy and/or  new target for chemical anthelmintics. However, these above immunological 
and biochemical assays have only been performed using a recombinant form of this protein 
(rFhGSTS1) [10, 13]. 
Unfortunately, vaccine trials with rFhGSTS1 did not significantly reduce the fluke challenge 
burden of infected goats, despite a reduction in lesions and necrotic tracts in the host liver 
tissue. Interestingly, previous experimental vaccinations with a native FhGST (nFhGST) 
isoenzyme mix likely incorporated FhGSTS1 protein and  provided almost a 70% reduction 
in worm burden in a cattle trial [16]. Furthermore, it has been shown recently that the 
nFhGSTS1 likely undergoes O-linked glycosylation [17] and this may be an important 
component of a protective vaccine formulation that has not been tested by current 
recombinant forms.  
To date, native GST studies are hampered in parasitic worms by lack of methodology to 
separate Sigma GST protein from other more abundant soluble GST classes such as Mu. 
Thus, the aim of this investigation was to isolate nFhGSTS1 from somatic extracts of adult F. 
hepatica through a two-step purification pipeline utilising GSH-agarose affinity 
chromatography, followed by cationic exchange chromatography in order to exploit the 
relatively high pI of FhGSTS1. Finally, nFhGSTS1 enrichment and purification were 
confirmed using 2DE, western blotting and tandem mass spectrometry.  
 
2. Materials and Methods 
2. 1 Protein sample preparation 
Adult liver fluke were obtained from freshly condemned sheep livers at a local abattoir in 
West Wales and were extensively washed in PBS then stored at -80°C until required. 
Somatic protein was extracted  on ice from 5 g of pooled adult F. hepatica in 1:10 (v/v) 
homogenisation buffer (10 mM sodium phosphate, 1 % v/v Triton X-100, pH 7.4, 1 tablet of 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich)) and centrifuged at 
21,000 x g for 30 min at 4°C, with the supernatant containing soluble proteins, including GST 
classes, collected, sonicated for three 15 second pulses and termed the somatic extract. 
2.2 Protein Concentration and GST Enzymatic Assay 
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Protein concentration was estimated using the method of Bradford [21]. The CDNB (1-
Chloro-2,4-dinitrobenzene) glutathione conjugation model substrate assay was used to 
measure GST activity [22]. The assay was completed in a 1 ml volume, with a final 
concentration of 100 mM potassium phosphate buffer (pH 6.5), 1 mM reduced glutathione, 1 
mM CDNB and absorbance changed measured at 340 nm for 3 min at 20 °C. The model 
substrate ethacrynic acid was also tested according to the method previously described [13].  
2.3 Glutathione-Agarose Affinity Chromatography 
A 1 ml volume matrix of GSH-agarose was prepared in column format according to the 
manufactures instructions (Sigma Ltd). In brief, the matrix was equilibrated with 20 column 
volumes (CVs) of 10 mM sodium phosphate buffer pH 7.4 containing 150 mM NaCl at a flow 
rate of 1.5 ml/min at room temperature. Somatic extract was passed through the column 
under gravity flow a total of six times. The column was washed with 20 CVs of the previously 
described equilibration buffer. The elution of bound protein was achieved by passing 5 CVs 
of elution buffer (50 mM Tris-HCl) pH 8.0 containing 5 mM GSH, at a flow rate of 1.0ml/min 
at room temperature. The collected eluent was then concentrated using 10 kDa MWCO 
centrifuge filter units (Amicon) and exchanged to 20 mM sodium phosphate buffer, pH 6.8.  
2.4 Cationic Exchange Chromatography 
Pre-packed 1 ml, HiTrap, fast-flow, carboxy-methyl (CM) Sepharose columns from G. E. 
Healthcare Ltd were linked to an automated ÄKTA prime plus system (G. E. Healthcare). All 
buffers and solutions for CM chromatography were passed through 0.45 µm cellulose filters. 
Initially, the system was washed and primed with buffer A (20 mM sodium phosphate buffer, 
pH 6.8) with the column installed with a system flow rate of 1.0 mL/min. Equilibration of the 
column was achieved by washing through 20 CVs of buffer A.  The GSH-affinity purified 
sample was loaded into the AKTA system at 4°C using a 500 µl sample loop and passed 
through the column at the optimal flow rate of 1.0 ml/min. The column was washed again 
with 20 CVs of buffer A. Adsorbed protein was eluted from the column using a single step 
increase in NaCl concentration achieved by passing 100% buffer B (20 mM sodium 
phosphate, 1.0 M NaCl, pH 6.8) through the column. PrimeView version 1.0 software (G. E. 
Healthcare) was used to monitor protein flow through, at 220 nm. Protein peaks in the UV 
chromatograph were collected in 1 ml fractions and protein containing fractions pooled for 
subsequent analyses.   
2.5. 1-Dimensional SDS-PAGE 
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Protein profiles were resolved by 1D SDS-PAGE. Samples were denatured in Laemmli 
sample buffer (BioRad) and heated to 95°C for 15 min and separated on a 12.5% 
acrylamide gel using a mini-Protean kit (Biorad) equilibrated with TGS gel running buffer (25 
mM Tris, 192 mM glycine, 0.1 % w/v SDS, pH 8.6). The protein separation was completed at 
70 V for 30 min and then 150 V for 90 min. Proteins were visualised using colloidal 
Coomassie staining [22] and imaged using a GS-800 densitometer (Biorad) and analysed 
with QuantityOne software (Biorad).  
2.6. 2-Dimensional  electrophoresis  
Isoelectric focusing was carried out using 7 cm linear pH 3-10 immobilized Readystrip™ IPG 
strips (BioRad). In brief, the IPG strips were rehydrated for 16 hrs with a solution comprising 
of the protein sample and buffer Z (8 M urea, 2 % w/v CHAPS, 33 mM DTT, 0.5 % v/v 
ampholytes   pH 3-10). The hydrated strips were focused using a Protean Kit (Biorad) for 
10,000 VH at 20°C. After focusing the IPG strips were placed in equilibration buffer (50 mM 
Tris-HCl, 6 M urea, 30 % v/v glycerol, 2 % w/v SDS, pH 6.8) containing 10 mg/ml DTT, for 
15 min at room temperature. A second equilibration step followed in which the IPG strip was 
placed in same equilibration buffer containing 25 mg/ml IAA. After equilibration the IPG was 
placed on to a 12.5 % acrylamide gel and fixed in position with molten agarose. Separation 
by molecular weight was performed according to the conditions for 1D SDS-PAGE. 
2.7. Western Blotting  
Western blotting was performed using a mini blot kit (Biorad), with the protein transferred 
from 1D SDS-PAGE 12.5 % acrylamide gels to nitrocellulose membrane. Prior to blotting, 
the gels and membranes were soaked in western blot equilibration buffer (25 mM Tris, 192 
mM glycine, 20 % methanol, pH 8.3) for 20 min. Transfer of protein to membrane was 
performed over a two hour period at 40 V. Transfer was confirmed by amido black staining 
(0.1 % w/v amido black, 45 % v/v methanol, 10 % v/v acetic acid) for 1 min. The membrane 
with transferred protein was subject to three 10 min washes in Tween-tris-buffered saline 
(TTBS; 0.1 M Tris, 1 % v/v Tween, 0.9 % w/v NaCl, pH 7.5) and blocked in TTBS with 5 % 
w/v powdered skimmed milk, overnight at 4 °C. 
Immuno-detection of Mu and Sigma class FhGSTs followed the protocol of Morphew et al. 
[24]. Briefly, the blotted nitrocellulose membrane was blocked in TTBS with 1 % w/v 
skimmed milk powder. For the detection of Mu GST classes, anti-Mu Schistosoma 
japonicum polyclonal antibodies (Sigma-Aldrich) raised in rabbit were used as parasitic 
flatworm Mu class representatives at a concentration of 1: 5000 (v/v) and for Sigma GST 
class anti-FhGSTS1 polyclonal antibodies raised in rabbits were used at a concentration of 
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1:30,000 (v/v).  The membranes were incubated with primary antibodies for 60 min at room 
temperature. Following three washes in TBS, the membranes were incubated in TTBS with 
anti-goat and anti-rabbit IgG alkaline phosphatase secondary antibodies (Sigma Ltd) at a 
concentration of 1: 30,000 for 60 min at room temperature. Visualisation of antibody binding 
was developed using the BCIP/NBT system [25].  
2.8 Protein Identification by Mass Spectrometry 
Protein spots were excised from the 2D SDS-PAGE gel and destained in three washes of 50 
mM ammonium bicarbonate (pH 8) and acetonitrile, at a 1:1 ratio, at 37°C. The gel pieces 
were dehydrated in acetonitrile for 15 min at 37°C followed by air drying at 50°C until all the 
liquid was removed. The gel pieces were swollen with 50 mM ammonium bicarbonate 
containing sequencing grade modified trypsin (Promega), at a concentration of 10 µg/µl, and 
incubated at 37°C overnight. 20 µl of double distilled water was added and the samples 
agitated for 10 min and the supernatant was collected. To the gel piece, 50 µl of 50 % (v/v) 
50 mM ammonium bicarbonate (pH 8), 5 % (v/v) formic acid was added and agitated for a 
further 60 min after which the supernatant was collected and mixed with the previously 
collected supernatant. The mix was dried using a speed vacuum and stored at -20°C until 
required. The samples were reconstituted in 20 µl of 1% (v/v) formic acid and centrifuged at 
3000 x g for 3 min to remove particulates, with 15 µl of the supernatant collected and placed 
in a sterile tube.  
Protein spot samples were analysed using liquid Chromatography tandem mass 
spectrometry (Agilent 6550 iFunnel Q-TOF) coupled to a HPLC-Chip (1200 series, Agilent 
Technologies, Cheshire, UK). The HPLC-Chip/Q-TOF system was equipped with a capillary 
loading pump (1200 series, Agilent Technologies) and a nano pump (1200 series, Agilent 
Technologies).  Sample injection was conducted with a micro auto sampler (1100 series, 
Agilent Technologies), where 1 µl of sample in 0.1% v/v formic acid was loaded on to the 
enrichment column at a flow of 2.5 µL/min followed by separation at a flow of 300 nL/min.  A 
Polaris Chip was used (G4240-62030, Agilent Technologies), comprising a C18 
enrichment/trap column (360 nl) and a C18 separation column (150 mm x 75 Âµm), where 
ions were generated at a capillary voltage of 1950 V. The solvent system was: solvent A 
(ultra-pure water with 0.1% v/v formic acid), and solvent B (90% v/v acetonitrile with 0.1% v/v 
formic acid). The liquid chromatography was performed with a piece-linear gradient using 3-
8% of solvent B over 0.1 minutes, 8-35% solvent B over 14.9 minutes, 35-90% solvent B 
over 5 minutes and hold at 90% solvent B for 2 minutes. Tandem mass spectrometry was 
performed in AutoMS2 mode in the 300-1700 Da range, at a rate of 5 spectra per second, 
performing MS2 on the 5 most intense ions in the precursor scan. Masses were excluded for 
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0.1 min after MS/MS was performed. Reference mass locking was used for internal 
calibration using the mass of 391.2843 Da. 
The data was filtered by molecular feature and exported as a MASCOT generic file (MGF). 
Using a local ‘in house’ MASCOT database (www.matrixscience.com) of the F. hepatica 
genome, the acquired MGF files submitted for a MS/MS ion search, using parameters 
previously described [24]. Homology was determined to be significant (p<0.05) for proteins 
with MASCOT ion scores greater than 32. The transcript identities were then searched at 
WormBase ParaSite (https://parasite.wormbase.org/index.html) in order to obtain the 
primary sequence of the protein. Protein identity was then confirmed by submitting the 
acquired primary sequence to blastp (www.ncbi.nlm.nih.gov) search against non-redundant 
protein sequences. 
3. Results 
5 g of adult F. hepatica worms yielded 105 mg of soluble somatic protein with a total CDNB 
glutathione conjugating activity of 173161 nmol.min-1, thus with a somatic GST specific 
activity of 1651 ± 96.5 nmol.min-1.mg-1protein. The first stage of the purification separated 
the GST isoenzyme mix from the somatic extract protein using GSH-affinity chromatography. 
The step removed approximately 96% of the somatic protein and the isolated proteins had 
8.4 fold enrichment in GST specific activity (13866 ± 906.6 nmol.min-1.mg-1protein), which 
accounted for 32.6 % of the starting CDNB glutathione conjugating activity present in the 
somatic extract (Table 1).   
 
 
Cationic exchange (CM-Sepharose) was used to isolate basic pI nFhGSTS1 away from 
other acidic and near neutral pI GSH-agarose binding GSTs. This second stage required 
optimisation of the initial pH conditions i.e. adsorption of nFhGSTS1 and the removal of the 
non-interacting Mu class FhGSTs. nFhGSTS1 was predicted to have a pI of 8.86 using the 
compute pI/MW tool (http://www.expasy.org/proteomics) and this was similar to the 
published experimental value of 8.56 [11]. Thus, purifications were carried out with various 
equilibration buffer pH ranges and the optimal conditions determined to be at pH 6.8. Under 
the optimised conditions, a single elution peak was observed in the UV chromatogram 
(Figure 1A) when the column was washed with 100% buffer B. Due to the low concentration 
of eluted protein, fractions 44 and 45 were pooled and determined to have a specific activity 
of 1471 ± 345.5 nmol.min-1.mg-1protein (Table 1).  The CM-Sepharose purified sample 
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produced a single band on 1D SDS-PAGE with an approximate molecular weight of 25 KDa 
(Figure 1B). Although classes of FhGSTs were not identified at this stage when separated by 
reduced 1D SDS-PAGE Mr, a single protein band of the CM-Sepharose eluent was noted 
when compared to the doublet protein bands produced from the GSH-affinity purified and 
CM-Sepharose unbound fractions (Figure 1B).  
 
 
Figure 1. Purification of FhGSTS1. A) The elution profile of protein bound to CM-Sepharose 
equilibrated to pH 6.8. Removal of protein from the column was achieved through a single 
step increase in NaCl concentration, shown by the increase in conductivity (dashed line). B) 
1D SDS-PAGE gel stained with colloidal Coomassie showing different stages of purification,  
1) GSH-affinity purified protein, 2) Cationic exchange unbound flow through protein, 3) CM-
Sepharose purified protein 
 
The eluted fraction of the CM-Sepharose purification produced a significant signal when 
subjected to western blotting with an anti-FhGSTS1 polyclonal antibody and developed 
using the NBT/BCIP method (Figure 2). Importantly, the same fraction did not cross-react 
with an anti-Mu class GST antibody. The unbound flow through fractions of the CM-
Sepharose column were recognised by both anti-FhGSTS1 antibodies, albeit weakly, and 
with anti-Mu class GST antibodies (Figure 2).    
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Figure 2. Western blot analysis of the different stages of nFhGSTS1 purification, developed 
using NBT/BCIP system.  A total of 2 µg of protein was loaded onto each lane.1) GSH-
affinity purified GSTs 2) CM-Sepharose unbound flow through 3) CM-Sepharose purified R) 
recombinant FhGSTS1 control. A) Membrane probed with anti-mu class antibodies (1:5000 
dilution). B) Membrane probed with anti-sigma class antibodies (1:30,000). 
 
For further integrity, the CM-Sepharose eluted fractions were separated by 2D SDS-PAGE 
and resolved to a single protein spot with an estimated pI of 8.17 (Figure 3).  
 
 
Figure 3. Confirmation of nFhGST-S1 purity with 2DE.  1 µg of GSH-affinity and CM-
Sepharose purified sample were separated by 12.5% polyacrylamide/pI 3-10 and visualised 
using colloidal Coomassie stain. Tandem mass spectrometry identified the solitary protein 
spot as FhGSTS1 (Figure 4). 
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Analysis using MS/MS spectroscopy revealed that this protein spot consisted of a single 
protein which when matched to an ‘in house’ F. hepatica MASCOT database was confirmed 
to be FhGSTS1 (MASCOT Score 669; Accession no. 2WB9_A; fig. 4).  Identity was 
confirmed through the sequencing of 33 peptides relating to 7 distinct peptide sequences 
and providing sequence coverage of 33%.  The full protein identification results can be found 
in Supplementary Table 1. Importantly, no other protein spots were detected by the colloidal 
Coomassie stain showing that nFhGSTS1 is the only protein present in the sample and it 
remains stable throughout this method of purification (Figure 3). Furthermore, nFhGSTS1 
retained activity towards CDNB (Table 1) and also exhibited activity towards the model 
substrate ethacrynic acid with an average specific activity of 1482.25 nmol.min-1.mg-1protein 
(n=2), this was higher than the specific activity measured for rFhGSTS1 [13]. 
 
Figure 4.  Confirmation of nFhGSTS1 via MSMS.  A) Protein sequence of nFhGSTS1 
accession no. 2WB9_A. Highlighted in bold are the seven identified peptides during MSMS 
including the characteristic peptide of this GST (bold and underlined) which is highlighted in 
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B) Annotated tandem mass spectra from the analysis of the protein spot (Figure. 3) 
confirming the identity of the purified protein to be nFhGSTS1. 
 
4. Discussion 
This investigation has delivered a new pipeline for the production of purified nFhGSTS1 from 
somatic protein extracts of adult F. hepatica tissue. Importantly, the end-product of this two-
step process was a structurally stable and enzymatically active native protein, supporting 
robust immunological and biochemical studies. 
Interestingly, nFhGSTS1 exhibited greater ethacrynic acid glutathione conjugation activity 
and less CDNB glutathione conjugation activity than rFhGSTS1 [13].  The differences in 
substrate activities between the recombinant and the native form of FhGSTS1 further 
highlight the potential limitation of bacterial host protein production technology and lack of 
eukaryotic post-translational modifications may have had consequence on the previous 
rFhGSTS1 vaccine studies. Thus, native proteins may be required to fully understand host-
parasite interactions in order to realise liver fluke protective vaccines [28]. However, with 
respect to future research, native parasitic worm protein isolation strategies is challenging as 
it requires removing parasites from vertebrates with often  relatively low yield of final purified 
antigen.  In this study each batch of purification round required 5g of F. hepatica tissue to 
yield 50 µg of purified target protein to study.  
Previous proteomic work identified Sigma GST protein in more near neutral protein spots (pI 
7.1) along with Mu class GSTs in F. hepatica extracts [11]. This finding is further supported 
in this biochemical study as Sigma GST was also detected in the CM-Sepharose unbound 
fractions, suggesting that a more acidic modified form of nFhGSTS1 or an additional Sigma 
class GST may also be expressed. Native GSTs consist of two subunits, either as 
homodimers or heterodimers [22].  Thus, the formation of native heterodimeric FhGSTs with 
extended functions in liver fluke cannot be also be ruled out, especially as heterodimeric 
GSTs have recently been described in another parasitic flatworm, the cestode Echinococcus 
granulosus [27].  
In conclusion, our new methodology allows for the isolation of purified and active FhGSTS1 
or basic pI Sigma GSTs other sources for analytical biochemical and immunological studies, 
such as vaccination trials in rodent models. We envisage that the column bed volumes can 
be increased for more preparative studies.  
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Table 1. Purification of F. hepatica GSTs using GSH-agarose affinity chromatography and 
CM-Sepharose cation exchange chromatography. *Unit (U) defined as the amount of GST 
required to react with 1 nmol CDNB per min. Average specific activity was determined from 3 
replicates, ± S.D. 
 
Fraction  Protein (mg)  Specific activity 
(U*/mg) 
Total activity (U)  
Somatic extract  104.9   1651.0   +/-  96.5 173161.1 
GSH-affinity      4.1 13866.4  +/- 906.6   56436.1 
CM-Sepharose         0.05   1471.5  +/- 345.5         73.6 
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